Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company is headquartered in Westminster, Colorado.
52W High
$2.94
52W Low
$0.42
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.50
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
N/A
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
N/A
Ownership
Source: Overview
Insiders (1–5% typical)
0.00%
Institutions (25–75% balanced)
0.00%
Shares Outstanding
0
Float
39,485,900
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
As of 2025-06-30 (Overview)
Revenue (TTM)
35,990,000
Gross Profit (TTM)
30,473,000
EPS (TTM)
N/A
Profit Margin (>10% good)
-0.87%
Operating Margin (TTM) (higher better)
-0.65%
ROE (TTM) (>15% strong)
N/A
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
0.52
Momentum
Bearish momentumValue
-0.0187
Previous
-0.0285
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025